首页> 外文期刊>Breast Cancer Research and Treatment >Ductal Breast Carcinomas with Whole Chromosome Gains as a Particular Subset of Near-Diploid Tumors with Different Metastasis Free Survival
【24h】

Ductal Breast Carcinomas with Whole Chromosome Gains as a Particular Subset of Near-Diploid Tumors with Different Metastasis Free Survival

机译:具有全染色体增益的乳腺导管癌作为不同转移免费生存率的近二倍体肿瘤的一个特殊子集

获取原文
获取原文并翻译 | 示例
           

摘要

We recently proposed the existence of a subtype of slightly hyperdiploid ductal breast cancers with cytogenetic alterations differing from those usually observed in the majority of these tumors. We aimed to establish whether these tumors, which represent about 50% of those with a DNA index (DI) comprised between 1.1 and 1.3, correspond to a particular clinicopathological entity. A retrospective study of 1771 patients operated for ductal carcinomas was performed. Three classes of tumors constituted according to DI were compared for the usual clinicopathological factors and clinical outcome. About 690 tumors (39%) were diploid/hypodiploid (DI < 1.1), 134 (7.6%) were hyperdiploid (1.1 ≤ DI < 1.3) and 947 (53.4%) were polyploid (DI ≥ 1.3). Median follow-up time was 106 months (range 1–177). Polyploid tumors were significantly associated with large tumor size, advanced clinical stage, high histological grade and S-phase fraction (SPF), positive lymph nodes and loss of steroid receptors. Hyperdiploid and diploid/hypodiploid tumors were similar for all the variables except SPF which was significantly higher in hyperdiploid tumors (p < 0.001). Overall survival was similar in hyperdiploid and diploid/hypodiploid tumors in univariate and multivariate analysis, while hyperdiploid tumors were significantly related to a poorer metastasis free survival, both in univariate (p = 0.023) and multivariate analysis (p = 0.031). Despite very close initial clinicopathological and biological characteristics, hyperdiploid tumors differed from diploid/hypodiploid tumors by a higher risk of metastasis, possibly related to their increased SPF.
机译:我们最近提出了一种轻度超二倍体导管型乳腺癌的亚型,其细胞遗传学改变与大多数这些肿瘤中通常观察到的不同。我们旨在确定这些肿瘤是否代表特定的临床病理实体,这些肿瘤约占DNA指数(DI)在1.1和1.3之间的50%。对1771例行导管癌的患者进行了回顾性研究。比较了根据DI构成的三类肿瘤的常见临床病理因素和临床结局。二倍体/次二倍体(DI <1.1)约690个肿瘤(39%),超二倍体(1.1≤DI <1.3)134个(7.6%)和多倍体(DI≥1.3)947个(53.4%)。中位随访时间为106个月(范围1–177)。多倍体肿瘤与大肿瘤,临床晚期,高组织学分级和S期分数(SPF),淋巴结阳性和类固醇受体的丢失密切相关。除SPF外,所有变量的超二倍体和二倍体/二倍体肿瘤均相似,而SPF在超二倍体肿瘤中明显更高(p <0.001)。在单变量和多变量分析中,高二倍体和二倍体/二倍体肿瘤的总生存率相似,而在单变量(p = 0.023)和多变量分析(p = 0.031)中,高二倍体肿瘤与较差的无转移生存率显着相关。尽管最初的临床病理和生物学特征非常接近,但超二倍体肿瘤与二倍体/次二倍体肿瘤的区别在于转移风险更高,可能与SPF升高有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号